News

December 17, 2020, Coralville, IA – Emmyon is pleased to announce that it has received a new Phase II Small Business Innovation Research (SBIR) award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the U.S. National Institutes of Health (NIH).  The funding will support development of novel pharmaceutical compounds for skeletal muscle atrophy, obesity and type 2 diabetes.  We’re very grateful to NIAMS and the NIH for their continued support of these efforts.

August 31, 2020, Coralville, IA – Emmyon is honored and grateful to announce that it has been included in the Small Business Showcase of the National Institute on Aging (NIA), a division of the U.S. National Institutes of Health. Please use this link to visit the NIA Small Business Showcase and read about the work Emmyon is conducting.

August 23, 2020, Coralville, IA – Emmyon is pleased to announce that patent offices in the US, Europe, Canada, Israel and Hong Kong have issued 7 new patents for compositions and/or uses of small molecules including the natural compounds ursolic acid and tomatidine, other recently discovered natural compounds that increase muscle mass, and several recently discovered novel small molecule inhibitors of skeletal muscle atrophy and obesity.  These new patents increase Emmyon’s IP portfolio to 27 granted patents in the US, Europe, Canada, Japan, China, Australia, Israel and Hong Kong, with many additional pending patent applications in major markets around the world.

January 17, 2020, Coralville, IA – In collaboration with colleagues at the University of Iowa and the Buck Institute for Research on Aging, Emmyon scientists Scott Ebert and Chris Adams published a new paper today describing a previously unknown mechanism of skeletal muscle atrophy.

The paper, entitled “Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C/EBPβ” was published in the Journal of Biological Chemistry. To view the paper, please click here.

January 2, 2020, Coralville, IA – Emmyon is pleased to announce that the US, Chinese and Israeli patent offices have issued several new patents for uses of ursolic acid and tomatidine.  These new patents significantly expand Emmyon’s IP coverage around ursolic acid and tomatidine.

December 1, 2019, Coralville, IA – Emmyon is delighted to announce that its Vice President of Chemistry, Dr. John Talley, has been named again (for the fifth year in a row) to the highly prestigious Power List of The Medicine Maker magazine.  The Medicine Maker Power List is comprised of the world’s 100 most influential people in drug discovery and development.